Sierra Eye Associates

Recent papers from Sierra Eye Associates

1. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trialThe Lancet · 2023
2. Safety and efficacy of topical OCS-01 ophthalmic suspension for the treatment of diabetic macular oedema: stage 1 of a multicentre, double-blind, randomised, vehicle-controlled phase 2/3 trialEClinicalMedicine · 2026
3. Pooled Analyses of Anatomic and Visual Function Data of Revakinagene Taroretcel-lwey in Participants with Macular Telangiectasia Type 2Ophthalmology Retina · 2026
4. Aflibercept biosimilar use and real-world outcomes in various retinal diseases: the AURA Korea studyScientific Reports · 2026
5. Visual and Anatomic Outcomes of Faricimab in Naïve Neovascular Age-Related Macular Degeneration with Subretinal Hemorrhage: A Multi-Centre Retrospective AnalysisClinical ophthalmology · 2026
6. An update on the port delivery system with ranibizumab for retinal diseasesExpert Opinion on Drug Delivery · 2026
7. Reduction in Pigment Epithelial Detachment Thickness with Faricimab vs Aflibercept 2 mg During Head-to-Head Dosing in TENAYA/LUCERNEOphthalmology Science · 2026
8. Four-Year Outcomes of Faricimab in Diabetic Macular EdemaOphthalmology · 2026
9. A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial InsightsEye · 2026
10. Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience—ROSE Korea StudyScientific Reports · 2026
11. Differential Visual Outcomes in Neovascular AMD Based on Ellipsoid Zone Integrity and Fluid Presence: Insights from a Phase III TrialDiagnostics · 2025
12. Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular EdemaNEJM Evidence · 2025
13. Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein OcclusionOphthalmology Retina · 2025
14. Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular DegenerationAmerican Journal of Ophthalmology · 2025
15. Sozinibercept (Anti-VEGF-C/-D) Combined with Ranibizumab for Polypoidal Choroidal Vasculopathy: Phase IIb Predefined Subgroup AnalysisOphthalmology Science · 2025
16. Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular EdemaJAMA Ophthalmology · 2025
17. Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE studyEye · 2024
18. Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular RetinopathiesInvestigative Ophthalmology & Visual Science · 2024
19. Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINEOphthalmology Retina · 2024
20. Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab InjectionsOphthalmology Retina · 2024